These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8478911)

  • 1. Design and modeling of new platelet-activating factor antagonists. 1. Synthesis and biological activity of 1,4-bis(3',4',5'-trimethoxybenzoyl)-2-[[(substituted carbonyl and carbamoyl)oxy]methyl]piperazines.
    Lamouri A; Heymans F; Tavet F; Dive G; Batt JP; Blavet N; Braquet P; Godfroid JJ
    J Med Chem; 1993 Apr; 36(8):990-1000. PubMed ID: 8478911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and modeling of new platelet-activating factor antagonists. 2. Synthesis and biological activity of 1,4-bis-(3',4',5'-trimethoxybenzoyl)-2-alkyl and 2-alkyloxymethylpiperazines.
    Tavet F; Lamouri A; Heymans F; Dive G; Touboul E; Blavet N; Godfroid JJ
    J Lipid Mediat Cell Signal; 1997 Jan; 15(2):145-59. PubMed ID: 9034961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and platelet-activating factor (PAF)-antagonistic activities of 1,4-disubstituted piperazine derivatives.
    Fukushi H; Mabuchi H; Itoh K; Terashita Z; Nishikawa K; Sugihara H
    Chem Pharm Bull (Tokyo); 1994 Mar; 42(3):541-50. PubMed ID: 8004699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and platelet-activating factor (PAF)-antagonistic activities of trisubstituted piperazine derivatives.
    Fukushi H; Mabuchi H; Terashita Z; Nishikawa K; Sugihara H
    Chem Pharm Bull (Tokyo); 1994 Mar; 42(3):551-9. PubMed ID: 8004700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAF receptor and "Cache-oreilles" effect. Simple PAF antagonists.
    Lamotte-Brasseur J; Heymans F; Dive G; Lamouri A; Batt JP; Redeuilh C; Hosford D; Braquet P; Godfroid JJ
    Lipids; 1991 Dec; 26(12):1167-71. PubMed ID: 1668113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships in platelet-activating factor (PAF antagonists). 6. Synthesis and in vitro antagonistic activities of 2-substituted 5-oxotetrahydrofurans.
    Favre E; Heymans F; Redeuilh C; Batt JP; Massicot F; Blavet N; Braquet P; Godfroid JJ
    J Lipid Mediat; 1992 Feb; 5(1):23-40. PubMed ID: 1449553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-(3-Pyridyl)thiazolidine-4-carboxamides. 1. Novel orally active antagonists of platelet-activating factor (PAF).
    Nagaoka H; Hara H; Suzuki T; Takahashi T; Takeuchi M; Matsuhisa A; Saito M; Yamada T; Tomioka K; Mase T
    Chem Pharm Bull (Tokyo); 1997 Oct; 45(10):1659-64. PubMed ID: 9353894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PAF inhibitory activity of diketopiperazines: structure-activity relationships.
    Shimazaki N; Shima I; Okamoto M; Yoshida K; Hemmi K; Hashimoto M
    Lipids; 1991 Dec; 26(12):1175-8. PubMed ID: 1819704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel class of platelet activating factor (PAF) antagonists. I. Synthesis and structure-activity studies on PAF-sulfonamide isosteres.
    Tsuri T; Haga N; Matsui T; Kamata S; Kakushi H; Uchida K
    Chem Pharm Bull (Tokyo); 1992 Jan; 40(1):75-84. PubMed ID: 1605805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PAF receptor structure: a hypothesis.
    Godfroid JJ; Dive G; Lamotte-Brasseur J; Batt JP; Heymans F
    Lipids; 1991 Dec; 26(12):1162-6. PubMed ID: 1668112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
    Carceller E; Merlos M; Giral M; Balsa D; García-Rafanell J; Forn J
    J Med Chem; 1996 Jan; 39(2):487-93. PubMed ID: 8558517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationships in platelet-activating factor (PAF). 7. Tetrahydrofuran derivatives as dual PAF antagonists and acetylcholinesterase inhibitors. Synthesis and PAF-antagonistic activity.
    Le Texier L; Favre E; Redeuilh C; Blavet N; Bellahsene T; Dive G; Pirotzky E; Godfroid JJ
    J Lipid Mediat Cell Signal; 1996 May; 13(3):189-205. PubMed ID: 8816984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and modeling of new platelet-activating factor antagonists. 3. Relative importance of hydrophobicity and electronic distribution in piperazinic series.
    Heymans F; Dive G; Lamouri A; Bellahsene T; Touboul E; Huet J; Tavet F; Redeuilh C; Godfroid JJ
    J Lipid Mediat Cell Signal; 1997 Jan; 15(2):161-73. PubMed ID: 9034962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity relationships in platelet-activating factor (PAF). 10. From PAF antagonism to inhibition of HIV-1 replication.
    Serradji N; Bensaid O; Martin M; Kan E; Dereuddre-Bosquet N; Redeuilh C; Huet J; Heymans F; Lamouri A; Clayette P; Dong CZ; Dormont D; Godfroid JJ
    J Med Chem; 2000 Jun; 43(11):2149-54. PubMed ID: 10841793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of PAF-induced human platelet aggregation by antithrombotic nipecotomides.
    Herron D; Dillingham EO; Lyman BA; Zheng X; Bond SE; Salgia SR; Gollamudi R
    Prostaglandins Leukot Essent Fatty Acids; 1995 May; 52(5):309-18. PubMed ID: 7630919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationships in platelet-activating factor. 12. Synthesis and biological evaluation of platelet-activating factor antagonists with anti-HIV-1 activity.
    Serradji N; Martin M; Bensaid O; Cisternino S; Rousselle C; Dereuddre-Bosquet N; Huet J; Redeuilh C; Lamouri A; Dong CZ; Clayette P; Scherrmann JM; Dormont D; Heymans F
    J Med Chem; 2004 Dec; 47(25):6410-9. PubMed ID: 15566310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet activating factor antagonists: synthesis and structure-activity studies of novel PAF analogues modified in the phosphorylcholine moiety.
    Takatani M; Yoshioka Y; Tasaka A; Terashita Z; Imura Y; Nishikawa K; Tsushima S
    J Med Chem; 1989 Jan; 32(1):56-64. PubMed ID: 2909744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PAF-receptor. 1. 'Cache-oreilles' effect of selected high-potency platelet-activating factor (PAF) antagonists.
    Dive G; Godfroid JJ; Lamotte-Brasseur J; Batt JP; Heymans F; Dupont L; Braquet P
    J Lipid Mediat; 1989; 1(4):201-15. PubMed ID: 2562434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1,4-Dihydropyridines as antagonists of platelet activating factor. 1. Synthesis and structure-activity relationships of 2-(4-heterocyclyl)phenyl derivatives.
    Cooper K; Fray MJ; Parry MJ; Richardson K; Steele J
    J Med Chem; 1992 Aug; 35(17):3115-29. PubMed ID: 1507200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analogues of platelet activating factor. 6. Mono- and bis-aryl phosphate antagonists of platelet activating factor.
    Wissner A; Carroll ML; Green KE; Kerwar SS; Pickett WC; Schaub RE; Torley LW; Wrenn S; Kohler CA
    J Med Chem; 1992 May; 35(9):1650-62. PubMed ID: 1578493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.